Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease

被引:34
作者
Horowitz, Mia [1 ]
Braunstein, Hila [1 ]
Zimran, Ari [2 ,3 ]
Revel-Vilk, Shoshana [2 ,3 ]
Goker-Alpan, Ozlem [4 ]
机构
[1] Tel Aviv Univ, Schmunis Sch Biomed & Canc Res, IL-69978 Tel Aviv, Israel
[2] Shaare Zedek Med Ctr, Gaucher Unit, Jerusalem, Israel
[3] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
[4] Lysosomal & Rare Disorders Res & Treatment Ctr LD, Fairfax, VA USA
关键词
Gaucher disease; Glucocerebrosidase (GCase); Parkinson disease; Misfolding; Unfolded Protein Response (UPR); UNFOLDED PROTEIN RESPONSE; SPHINGOLIPID ACTIVATOR PROTEINS; HUMAN GLUCOCEREBROSIDASE GENE; ENZYME REPLACEMENT THERAPY; ALPHA-SYNUCLEIN; ENDOPLASMIC-RETICULUM; BETA-GLUCOSIDASE; GBA MUTATIONS; RECOMBINANT GLUCOCEREBROSIDASE; SUBSTANTIA-NIGRA;
D O I
10.1016/j.addr.2022.114402
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Lysosomes have a critical role in maintaining normal cellular homeostasis mediated by their involvement in secretion, plasma membrane repair, cell signaling and energy metabolism. Lysosomal storage disorders (LSDs) are a group of approximately 50 rare disorders caused by lysosomal dysfunction that occur due to mutations in a gene of a lysosomal protein. Gaucher disease (GD), an autosomal recessive disorder and one of the most common LSDs, is caused by the deficiency of the lysosomal enzyme acid-beta-glucocerebrosidase (GCase), due to biallelic mutations in the GBA1 gene. Reduced GCase activity leads to the accumulation of glucosylceramide (GlcCer), which is deacylated by lysosomal acid ceramidase to a toxic metabolite, glucosylshpingosine (GlcSph). Most GBA1 variants are recognized as misfolded in the ER, where the retention for refolding attempts initiates stress and activates the stress response known as the Unfolded Protein Response (UPR). The distinct clinical subtypes of GD are based on whether there is primary involvement of the central nervous system. Type 1 GD (GD1) is the nonneuropathic type, however, the recent recognition of the association of GD with the development of parkinsonism defies this classification. Patients with GD1 and carriers of GBA1 mutations are at risk for the development of parkinsonian manifestations. Parkinson disease (PD), the second most prevalent neurodegenerative disease, culminates in a movement disorder with the premature death of the patients. In PD and related disorders, collectively called synucleinopathies, the hallmark pathology is a-synuclein positive aggregates referred to as Lewy bodies or Lewy neurites and the death of dopaminergic neurons. While PD is mostly sporadic, in similar to 5-10% of cases, the disease results from pathogenic variants in a growing number of genes. The most common genetic cause of PD is mutations in GBA1. Two mechanisms have been proposed for this link: (A) a "gain of function" mechanism, in which mutant GCase (protein) contributes to aggregate formation and to the development of PD, and the (B) "haploinsufficiency" ("loss of function") model, suggesting that one normal GBA1 allele is insufficient to carry adequate GCase activity and functional deficiency of GCase impedes a-synuclein metabolism. Lysosomal dysfunction, compromised autophagy and mitophagy further enhance the accumulation of a-synuclein, which results in the development of PD pathology. The present review will elaborate on the biology of GD, its association with PD and related disorders, and discuss the possible mechanisms underlying this association. (c) 2022 Elsevier B.V. All rights reserved.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Lysosomal Storage Disorders and Parkinson's Disease: Gaucher Disease and Beyond
    Shachar, Tamar
    Lo Bianco, Christophe
    Recchia, Alessandra
    Wiessner, Christoph
    Raas-Rothschild, Annick
    Futerman, Anthony H.
    MOVEMENT DISORDERS, 2011, 26 (09) : 1593 - 1604
  • [2] Molecular mechanisms of the ambroxol action in Gaucher disease and GBA1 mutation-associated Parkinson disease
    Cyske, Zuzanna
    Gaffke, Lidia
    Rintz, Estera
    Egrzyn, Grzegorz W.
    Pierzynowska, Karolina
    Wisniewska, Karolina
    NEUROCHEMISTRY INTERNATIONAL, 2024, 178
  • [3] The Neuroprotective Effects of Electroacupuncture on Parkinson's Disease and the Underlying Molecular Mechanisms
    Han, Qiuqin
    Chen, Peiqing
    Chen, Xiaorong
    Wang, Lijuan
    Huang, Renyan
    Li, Wenhui
    Liu, Guobin
    JOURNAL OF INTEGRATIVE NEUROSCIENCE, 2024, 23 (01)
  • [4] Parkinson disease: from pathology to molecular disease mechanisms
    Dexter, David T.
    Jenner, Peter
    FREE RADICAL BIOLOGY AND MEDICINE, 2013, 62 : 132 - 144
  • [5] Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson's disease
    Pitcairn, Caleb
    Wani, Willayat Yousuf
    Mazzulli, Joseph R.
    NEUROBIOLOGY OF DISEASE, 2019, 122 : 72 - 82
  • [6] Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease
    Wong, Yvette C.
    Krainc, Dimitri
    MOVEMENT DISORDERS, 2016, 31 (11) : 1610 - 1618
  • [7] The emerging role of autophagic-lysosomal dysfunction in Gaucher disease and Parkinson's disease
    Kinghorn, Kerri J.
    Asghari, Amir M.
    Castillo-Quan, Jorge Ivan
    NEURAL REGENERATION RESEARCH, 2017, 12 (03) : 380 - 384
  • [8] The emerging role of autophagic-lysosomal dysfunction in Gaucher disease and Parkinson's disease
    Kerri J.Kinghorn
    Amir M.Asghari
    Jorge Iván Castillo-Quan
    Neural Regeneration Research, 2017, 12 (03) : 380 - 384
  • [9] Molecular mechanisms underlying the neuroprotection of environmental enrichment in Parkinson's disease
    Alarcon, Tamara Andrea
    Presti-Silva, Sarah Martins
    Toniato Simoes, Ana Paula
    Ribeiro, Fabiola Mara
    Wanderley Pires, Rita Gomes
    NEURAL REGENERATION RESEARCH, 2023, 18 (07) : 1450 - 1456
  • [10] Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease
    Zeng, Xian-Si
    Geng, Wen-Shuo
    Jia, Jin-Jing
    Chen, Lei
    Zhang, Peng-Peng
    FRONTIERS IN AGING NEUROSCIENCE, 2018, 10